Evaluation of a Physical Device for Medical Use (ADTPM 1) for Opioid Withdrawal Symptoms
A legfontosabb adatok
- Ki végzi
- Nu Eyne Co., Ltd.
- Hol
- Dél-Korea1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 24 fő, tervezett
- Kezdés
- 2025. máj. 30.
- Tervezett befejezés
- 2026. ápr. 6.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport színlelt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Neurostimulation
- Sham stimulation
- A regiszteradat frissítve
- 2025. július 22.
Ki vehet részt
- Életkor
- 19 év – 80 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 27 feltétel megnézéseKevesebb
Ki vehet részt
- Participants aged 19 to 80 years
- Participants currently dependent on opioids, whether prescribed or non-prescribed
- Participants who meet the criteria for opioid use disorder (OUD) according to DSM-5
- Participants with a Clinical Opiate Withdrawal Scale (COWS) score of 5 or higher
- Participants with a Numeric Rating Scale (NRS) pain score of less than 6
- Participants who have voluntarily decided to participate in the study and have provided written informed consent
- Participants who are willing to comply with the study protocol
Ki nem vehet részt
- Participants who have used long-acting opioids, such as methadone or buprenorphine, continuously for more than 5 days prior to screening
- Participants who have used methadone within 30 days prior to screening
- Participants who have used buprenorphine within 7 days prior to screening
- Participants with physiological dependence on alcohol or drugs other than opioids, tobacco, or marijuana
- Participants with implanted devices such as a pacemaker, cochlear implant, or neurostimulator
- Participants who are currently undergoing chemotherapy (Exception: Participation may be allowed if the investigator determines that participation poses no medical safety concerns for the participant)
- Participants with implanted metal or electronic devices in the head or neck area, including deep brain stimulators or pacemakers, as specified in the product precautions and contraindications (dental implants are exempt)
- Participants with cognitive impairment due to neurodevelopmental disorders (e.g., intellectual disability, developmental disorders, autism spectrum disorder) or neurodegenerative disorders (e.g., Alzheimer's disease, vascular dementia) that would make it difficult to undergo treatment with the investigational medical device
- Participants who are currently participating in another clinical trial or who have participated in another clinical trial within 30 days prior to screening
- Participants with any current uncontrolled or clinically significant medical condition
- Participants with a history of seizures or epilepsy
- Participants with a history of neurological disorders or traumatic brain injury
- Participants diagnosed with a major psychiatric disorder (psychosis, schizophrenia, or bipolar disorder)
- Participants with abnormal ear anatomy or ear infections
- Participants diagnosed with renal or hepatic failure
- Participants who are currently hospitalized due to a recent suicide attempt or who are persistently expressing suicidal intent
- Participants who are currently engaged in high-risk occupations (e.g., transportation workers, crane operators, heavy machinery operators, individuals working with sharp objects, or those requiring a high level of cognitive functioning)
- Participants who are pregnant or breastfeeding
- Female participants of childbearing potential who do not agree to abstain from sexual intercourse or to use medically accepted contraception* during the study period; *Medically accepted methods of contraception include: condoms, consistent oral contraceptive use (≥3 months use), injectables or implantable contraceptives, or intrauterine devices (IUDs)
- Participants who, in the opinion of the investigator, are deemed inappropriate for participation due to ethical concerns or potential impacts on study outcomes
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 19 és 80 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Dél-Korea.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study aims to evaluate the safety and efficacy of a physical device for medical use (ADTPM 1) applied to opioid withdrawal symptoms.
A vizsgálat 2 csoportja
- Experimental GroupA vizsgált kezelés
Experimental Group (Active Stimulation, n=12): Participants in this group will use the physical device for medical use (ADTPM 1) applied to the auricular region (ear and surrounding area) for 60 minutes (±10 minutes) per session, at least once daily and a minimum of 7 times per week, over a 4-week treatment period. Additional sessions may be conducted if participants require further relief of withdrawal symptoms. All assessments and permitted concomitant treatments will be administered in accordance with the study protocol.
Kezelés: Neurostimulation
- Control GroupSzínlelt kezelés, összehasonlításként
Control Group (Sham Stimulation, n=12): Participants in this group will use a sham stimulation device that does not deliver active stimulation. The sham device will be applied under the same schedule and conditions-60 minutes (±10 minutes) per session, at least once daily and 7 times per week for 4 weeks. All assessments and permitted concomitant treatments will be identical to those in the active stimulation group.
Kezelés: Sham stimulation
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Single Center, Double-Blind, Randomized, Sham-Controlled, Parallel Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of a Medical Device for the Treatment of Opioid Withdrawal Symptoms
- Kérdések a feltételekről
- Forrás: NCT07079215: ki vehet részt
- A regiszteradat frissítve
- 2025. július 22.